Transient Interferon-Driven Natural Killer Cell Activation in Acute Hepatitis C - Scorecard - MDSpire

Transient Interferon-Driven Natural Killer Cell Activation in Acute Hepatitis C

  • By

  • Benedikt Strunz

  • Qiuyao Zhan

  • Tanvi Khera

  • Julia Hengst

  • Marija Jankovic

  • Katja Deterding

  • Annika Niehrs

  • Markus Cornberg

  • Cheng-Jian Xu

  • Heiner Wedemeyer

  • Niklas K Björkström

  • the HepNet Acute HCV IV Study Group

  • Christoph D Spinner

  • Eckart Schott

  • Tania M Welzel

  • Guido Gerken

  • Hartwig Klinker

  • Ulrich Spengler

  • Johannes Wiegand

  • Julian Schulze zur Wiesch

  • Anita Pathil

  • Andreas Umgelter

  • Caroline Zöllner

  • Stefan Zeuzem

  • Armin Papkalla

  • Kristina Weber

  • Svenja Hardtke

  • Heiko von der Leyen

  • Armin Koch

  • Dorothee von Witzendorff

  • Michael P Manns

  • Kerstin Port

  • Bernhard Schlevogt

  • Marc Ringelhan

  • Ulrich Mayr

  • Judith Schrewe

  • Katharina Sosnowsky

  • Christoph Jochum

  • Gudrun Hilgard

  • Petra Schulze

  • Susanne Wiebecke

  • Ji-Eun Lee

  • Peter Hoffmann

  • December 29, 2025

  • 0 min

Share

Clinical Scorecard: Temporary Activation of Natural Killer Cells Induced by Interferon in Acute Hepatitis C Infection

At a Glance

CategoryDetail
ConditionAcute hepatitis C virus (HCV) infection
Key MechanismsType I interferon-driven activation of natural killer (NK) cells with an interferon-stimulated gene (ISG) signature
Target PopulationPatients with acute symptomatic HCV infection, primarily genotype 1
Care SettingClinical antiviral treatment setting with direct-acting antivirals (DAAs)

Key Highlights

  • A distinct subset of highly activated NK cells with a robust type I interferon imprint is present during acute HCV infection.
  • Activated NK cell populations normalize after DAA-mediated viral clearance but show a long-term phenotypic imprint compared to healthy controls.
  • NK cell activation and ISG expression are more pronounced in acute HCV than in chronic HCV infection.

Guideline-Based Recommendations

Diagnosis

  • Identify acute symptomatic HCV infection via clinical and virological assessment.
  • Use flow cytometry and single-cell RNA sequencing to characterize NK cell activation and ISG expression in research settings.

Management

  • Treat acute HCV infection with a 6-week course of ledipasvir/sofosbuvir (LDV/SOF) as per HepNet clinical trial protocol.
  • Recognize that direct-acting antivirals (DAAs) effectively clear the virus and restore NK cell activation profiles.

Monitoring & Follow-up

  • Monitor NK cell activation status longitudinally before, during, and after DAA treatment to assess immune response dynamics.
  • Observe normalization of activated NK cell subsets post-viral clearance.

Risks

  • Chronic HCV infection leads to impaired NK cell function, including reduced cytokine production and cytotoxicity.
  • Delayed or absent treatment may result in progression to liver cirrhosis with high morbidity and mortality.

Patient & Prescribing Data

15 patients with acute symptomatic HCV genotype 1 infection treated in a clinical trial setting

A 6-week regimen of LDV/SOF resulted in viral clearance in all patients, accompanied by normalization of NK cell activation.

Clinical Best Practices

  • Early identification and treatment of acute symptomatic HCV infection with DAAs to promote viral clearance and immune restoration.
  • Consider immunological profiling of NK cells to understand host antiviral responses in research contexts.
  • Recognize the role of type I interferons in driving NK cell activation during acute infection.

References

Original Source(s)

Transient Interferon-Driven Natural Killer Cell Activation in Acute Hepatitis C

  • by Benedikt Strunz, Qiuyao Zhan, Tanvi Khera, Julia Hengst, Marija Jankovic, Katja Deterding, Annika Niehrs, Markus Cornberg, Cheng-Jian Xu, Heiner Wedemeyer, Niklas K Björkström, the HepNet Acute HCV IV Study Group, Christoph D Spinner, Eckart Schott, Tania M Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze zur Wiesch, Anita Pathil, Andreas Umgelter, Caroline Zöllner, Stefan Zeuzem, Armin Papkalla, Kristina Weber, Svenja Hardtke, Heiko von der Leyen, Armin Koch, Dorothee von Witzendorff, Michael P Manns, Kerstin Port, Bernhard Schlevogt, Marc Ringelhan, Ulrich Mayr, Judith Schrewe, Katharina Sosnowsky, Christoph Jochum, Gudrun Hilgard, Petra Schulze, Susanne Wiebecke, Ji-Eun Lee, Peter Hoffmann

  • December 29, 2025

Related Content

Accessing Syringe Services Programs in the US: Analyzing Travel Time, Distance, and Associated Costs

When Time Is of the Essence: Hepatitis C Virus RNA Point-of-Care Testing in 15 Minutes Becomes a Reality

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.